anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
Carcinogenesis: Oral carcinogenicity studies were conducted in mice (100 weeks) and rats (106 weeks) at doses of up to 125 mg/kg/day. Plasma exposures (AUC) at the highest dose tested were approximately 150 (mice) and 240 times (rats) that in humans at the maximum recommended daily dose (MRDD) of 30 mg/day. There was no evidence of an increase in tumor incidence related to rizatriptan in either species.

Mutagenesis: Rizatriptan was neither mutagenic nor clastogenic in a battery of in vitro and in vivo genetic toxicity studies, including: the microbial mutagenesis (Ames) assay, in vitro mammalian cell mutagenesis and chromosomal aberration assays, and the in vivo chromosomal aberration assay in mouse.

Impairment of Fertility: In a fertility study in rats, altered estrus cyclicity and delays in time to mating were observed in females treated orally with 100 mg/kg/day rizatriptan. The no-effect dose was 10 mg/kg/day (approximately 15 times the human exposure at the MRDD). There were no other fertility-related effects in the female rats. There was no impairment of fertility or reproductive performance in male rats treated with up to 250 mg/kg/day (approximately 550 times the human exposure at the MRDD).
Nowadays, with technological developments, the use of new presentation techniques in addition to the methods used to develop knowledge, skills and practices in health sciences education is becoming increasingly widespread .Pecha kucha (PK) is an innovative form of presentation used around the world. PK, derived from the Japanese word meaning "chat", helps present creative works with visual images. Pecha kucha is a compact and effective presentation method consisting of 20 slides, each presented in 20 seconds This "20×20" format, which requires careful editing and develops the use of critical communication skills, serves as an innovative and valuable tool that allows the presenter to dynamically and systematically present important information worth sharing to the audience. Thanks to Pecha Kucha, the presenter conveys the topic quickly and clearly without deviating from the essence of the topic. PK may be superior to traditional PowerPoint presentations in terms of learning function. PK is as effective as traditional PowerPoint presentations in retaining information. It is stated that with the pecha kucha method, information can be presented in a more concise way, without any difference in quality, compared to a longer PowerPoint presentation. PK presentation, including visual and narrative presentation, does not take more than 7-8 minutes. It is stated that teachers and students prefer this technique due to its good presentation quality, increased eye contact and visual appeal, and attractiveness. In the literature, there is a lack of studies examining the knowledge and application skills of students regarding BLS education given using the Pecha Kucha method. In addition to contributing to the existing literature, this research will also contribute to determining the effect of basic life support training given with Pecha Kucha, a current presentation technique, on the learning and practice level of students studying in the field of health services.
The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or \< 25% of esophageal circumference (C1), and large varices or \> 25% of esophageal circumference (C2).
In clinical studies with finasteride tablets 1 mg (finasteride, 1 mg) in men 18 to 41 years of age, the mean value of serum prostate specific antigen (PSA) decreased from 0.7 ng/mL at ba seline to 0.5 ng/mL at Month 12. Further, in clinical studies with finasteride tablets 5 mg (fina steride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approxi mately 50%. Other studies with finasteride tablets 5 mg showed it may al so cau se de crea ses in serum PSA in the pre sen ce of pro state can cer. The se findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with fina steride. Any confirmed increa se f rom the lowest PSA value while on finasteride tablets may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5 α-reductase inhibitor. Non-compl iance to therapy with finasteride tablets may also affe ct PSA te st re sult s
Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
It has been reported that use of the Latarjet procedure for anterior shoulder instability increased 250% from 2008 to 2019. With this increase in use, it is imperative to minimize complications. At present, most literature focuses on male patients, with scant evidence regarding female patients. Outcomes are similar when female with male patients are compared, but female patients have greater postoperative visits to the emergency department than male patients, which requires specific attention during the postoperative period. In addition, the literature reporting complications in female versus male patients after Latarjet is conflicting; some studies show similar rates of complications, whereas other studies show greater rates of adverse events in female patients. Previous consensus statements recommended (1) careful dissection; (2) identification of the musculocutaneous and axillary nerves; (3) prevention of overlateralization of the graft; (4) the use of tranexamic acid to reduce blood loss; (5) accurate screw placement; and (6) careful preparation of the glenoid neck and coracoid to reduce rates of nonunion or delayed union.
INTRODUCTION: The 2021 American Association for the Study of Liver Disease (AASLD) Practice Guidance recommends albumin infusion when removing ≥5 L of ascites to prevent post-paracentesis circulatory dysfunction. However, the optimal criteria and scenarios for initiating albumin infusion subsequent to therapeutic paracentesis (TP) have been subject to limited scientific inquiry.
METHODS: We conducted a retrospective cohort study at a US academic healthcare center. Participants received elective, outpatient TP between July 2019 and December 2022. Patients with spontaneous bacterial peritonitis, post-TP clinical adjustments, and/or hospitalization were excluded. The institution strictly followed the AASLD Guidance. We used a sharp regression discontinuity (RD) design to estimate the effect of albumin infusion at the AASLD Guidance-recommended cutoff of 5 L on serum creatinine and sodium trajectory after TP.
RESULTS: Over the study period, 1,457 elective TPs were performed on 235 unique patients. Albumin infusion at the threshold of 5 L of ascites removal reduced serum creatinine levels by 0.046 mg/dL/d (95% confidence interval 0.003-0.116, P = 0.037) and increased serum sodium levels by 0.35 mEq/L/d (95% confidence interval 0.15-0.55, P = 0.001) compared with those who did not receive albumin infusion. The RD plots indicated worsened serum creatine/sodium levels after draining 3 L of fluid, approaching levels similar to or worse than with albumin infusion at 5 L or more.
DISCUSSION: Our RD models supported the 2021 AASLD Guidance with robust estimation of causal effect sizes at the cutoff level of 5 L. Nevertheless, the findings also highlight the need to further evaluate the efficacy of albumin infusion in patients who undergo elective TP and have 3-5 L of ascites removed.
Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted (actual penetration of the skin) at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli. The sham points aren't acupuncture points nor located on meridians \[2\].
Eligible active duty service members, retired or veterans who participated in rehabilitation programs at Department of Defense Advanced Rehabilitation Centers (Walter Reed National Military Medical Center, Center for the Intrepid-San Antonio Military Medical Center and/or the Naval Medical Center San Diego) will be considered for enrollment in this study. This study will look at service members who have undergone transfemoral, transtibial or bilateral lower extremity amputation or limb salvage procedures. Participants will receive fall prevention training on an instrumented treadmill (6, training sessions). Participants will receive three performance assessments:-immediately following completion of the treadmill training and at three and six months following the completion of the training. Post training, twice per month subjects will receive an email containing a follow up fall questionnaire monitoring if they have fallen and the circumstances surrounding their fall. If they do not have access to email, or if a timely response is not received from the email questionnaire which was sent out, subjects will be contacted by phone.
PURPOSE: To obtain an aerosol composition having excellent deodorant effect, use feeling and stability by containing a specific spherical silicone resin, inorganic powder and an aerosol propellant. CONSTITUTION: This composition contains 0.01-20wt.% of a spherical silicone resin having 0.5-15μm average particle diameter and 0.1-0.6 apparent specific gravity, 0.01-20wt.% inorganic powder as a water-soluble metallic salt (e.g. chlorhydroxylaluminum) and 5-99wt.% of an aerosol propellant (e.g. normal butane). Further, preferably 0.01-10wt.% of a nonionic surfactant having <8 HLB is mixed to have excellent stability. Otherwise, well-known components such as oils and fats, waxes, silicones, an antioxidant, organic powder, a surfactant, a fragrance, alcohols, an antiseptic, an ultraviolet ray absorber, a chelating agent, a wet retentive agent, a thickener, water, a refreshing agent, a bactericide and an antinflammatory agent are suitably mixed to prepare the objective aerosol composition.
1. A pharmaceutical composition suitable for parenteral administration having anti-inflammatory and analgesic property and being prepared and kept in a gas-inert atmosphere, characterized by the fact that it contains a 2-arylpropionic acid selected from the group consisting of ketoprofen, ibuprofen, naproxen, tiaprofenic acid, with a base selected from α-amino acid, droproizine and tromethamine in racemic as well as in enantiomeric form, in an aqueous solution having an osmolarity between 270 and 310 mOsrm/kg and at a pH in the range between 7.0 and 7.5, said solution being free of preservatives and of supporting substances. 2. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the d, 1-lysine salt of (R, S)-ketoproten and the inert gas is nitrogen. 3. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylanononium salt of the 2-arylpropionic acid is the 1-lysine salt of (R, S) -ketoprofen. 4. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the 1-lysine salt of R-ketoprofen. 5. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylanroonium salt of the 2-arylpropionic acid is the 1-dropropizine salt of R-ketoprofen. 6. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylancnoniuro salt of the 2-arylpropionic acid is the tromethamine salt of S-ketoprofen. 7. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylancnoniuro salt of the 2-arylpropionic acid is the tromethamine salt of R-ketoprofen. 8. A pharmaceutical composition according to Claim 1, characterized by the fact that the alkylancnonium salt of the 2-arylpropionic acid is the 1-lysine salt of S-ketoprofen. 9. Process for the preparation of the pharmaceutical composition according to Claim 1, characterized by that an alkylamrnonium salt of a 2-arylpropionic acid selected from the group consisting of ketoprofen, ibuprofen, naproxen and tiaprofenic acid with a base selected from α-amino acid, droproizine and tromethamine suitably dissolved in water for injectable preparation at a pH between 7.0 and 7.5 in an atmosphere of an inert gas and away from light.
An aqueous pharmaceutical solution suitable for parenteral administration contains reserpine or a salt thereof, e.g. sulphate or hydrochloride, which may be present up to 0.1 per cent, dissolved in a mixture of ethanol which may be present from 4 to 5 per cent, benzyl alcohol which may be present from 3 to 5 per cent, glycerine which may be present from 34 to 44 per cent, polyethylene glycol which may be of molecular weight about 300 and present from 36 to 42 per cent weight (gm.) to volume (c.c.) of the preparation, and water. The solution is prepared by dissolving the reserpine in the benzyl alcohol and then adding the ethanol, polyethylene glycol, glycerine and water.  The pH of the solution may be adjusted to 6.2 by addition of citric acid and may be sterilized by autoclaving or bacteriological filtration.
FIELD: medicine. SUBSTANCE: hydrogel contains acrylamide-base polymer obtained with the use of radical polymerization initial agent in apyrogenic water as dispersion medium. Hydrogel contains cross-linked polyacrylamide obtained with the use of biocompatible cross-linking agent, mainly methylene-bis-acrylamide, and preferably with the use of a mixture of ammonium persulfate and tetramethylethylenediamine as polymerization initiating agent. Preferable concentration of indicated polymer in hydrogel is from 3.5 to 9 wt.-%. Hydrogel is used for correction of cosmetic or functional defects by organ endoprosthesis, for intratissue depot drug of prolonged action making, for vital cavern tamponage. EFFECT: enhanced quality of hydrogel. 5 tbl, 2 dwg, 5 cl
Obesity is one of the most critical public health burdens worldwide. Its prevalence is increasing, as well as its comorbidities. The main comorbidity of obesity on the respiratory system is the obstructive sleep apnea syndrome (OSAS). The prevalence of OSAS in the obese population is around 45%. OSAS increased cardiovascular risk and decreased quality of life. The most alterable risk factor of OSAS is obesity. Therefore, weight loss is the cornerstone of the treatment. There is some evidence of the efficacy of weight loss surgery (lap band, sleeve gastrectomy, biliary pancreatic deviation, duodenal switch, and Roux-and-Y-gastric bypass) to improve OSAS. Current recommendations suggest bariatric surgery management for patients with a BMI \> 35kg/m2 and OSAS. However, most studies have limited scientific value (retrospective observational trials), and the follow-up of patients is limited, mainly due to patients' inadequate compliance. Moreover, until now, there is no reliable predictor for the percentage of reduction of AHI caused by weight loss. On the other hand, there is no approved treatment in patients presenting a BMI between 28 kg/m² to 34.9kg/m² and OSAS.

Endoscopic endoluminal approaches to address obesity have become an important topic of interest over the past decade. Endomina® (Endo Tools Therapeutics, Gosselies, Belgium) is a novel restrictive endoluminal approach. This new procedure permitted a weight loss of 29 % on average sustained at one year. This technique was not yet evaluated in patients with 28 kg/m2 ≤ BMI ≤ 34.9/m2 to improve OSAS.

The current feasibility study aims to evaluate the efficacy of an endoluminal gastric plication using an endoluminal-suturing device to improve severe OSAS in patients with above or equal to 28 kg/m², BMI until 34.9kg/m².
Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N═CC<, --CO--N< or --CS--N< as the partial structure --X . . . . . Y<; R a  and R b  are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Ring C is optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.
Each study participant will be admitted at IRCM one to five days after sensor insertion. Participants will be asked to change their pump catheter 24 to 36 hours prior to the intervention visit. On the day of the intervention visit, participants will have a standardized lunch (45-65g CHO for females and 60-80g CHO for males ) at 12:00 and will be asked not to eat afterwards (except for correction of hypoglycemia). Participants will be asked not to exercise (excluding light exercise such as walking or taking the stairs) the day before and the day of the intervention visit. Participants will be asked not to consume caffeine after 12:00 the day of the intervention. The day before the intervention and the day of the intervention, participants will be asked to refrain from alcohol consumption. Participants will be blinded to the strategy used during the exercise intervention. Participants will be admitted at IRCM at 14:00. A catheter will be installed for plasma glucose and insulin measurements. At 14:30, insulin basal rate will be reduced by 40% or 80% depending of randomization. At 15:30, participants will undertake a continuous exercise (60-minute exercise on the ergocycle at 60% of VO2 peak) or an interval exercise (2-minutes alternating intervals at 85% and 50% of VO2peak for 50-minutes, with 5-minutes at 45% VO2peak at the start and the end of exercise). As a safety measure, plasma glucose will be measured every 10 minutes. Participants will be blinded to sensor glucose levels as well as plasma glucose measurements. At 17:00, the participant will be discharged if glucose levels are above 5.5 mmol/L. Participants will be asked to eat a standardized dinner at home (45-65g CHO for females and 60-80g CHO for males). Participants will have the freedom to choose at what time they wish to have dinner but it will have to be similar on all intervention visits.
Smoking adults aged 18 years and older from disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
A strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
Consented participants will be randomly assigned to aerobic exercise regimen (AER) + Standard Rehabilitation(R+AER) or Standard Rehabilitation only (R) group. In order to determine the necessary time window for AER exercise treatment, TBI subjects will partake in supervised AER sessions for a period of 12 weeks. After a baseline evaluations follow-ups will take place at take place at weeks 4, 8 and 12. Thus each participants will be evaluated 4 times.
Participants will receive an intervention combining one session of motivational enhancement therapy with eight sessions of cognitive-behavioral coping skills therapy (MET+CBT). A contingency management procedure will be added to this intervention, providing reinforcement for completion of homework, as verified by call-ins to an Interactive Voice Recording (IVR) system. Outcomes will be compared to an MET+CBT intervention in which reinforcement will be provided for marijuana-free urine specimens, and to a control group that receives Case Management. Recruitment of 234 marijuana-dependent participants will occur over a three-year period. They will be randomly assigned to one of the three 9-session interventions. Treatment will be individual, manualized, and provided on an outpatient basis. Pretreatment assessments will obtain baseline data; follow-up assessments at three-month intervals for one year will evaluate marijuana use outcomes, other drug or alcohol use, and psychosocial functioning. It is anticipated that the intervention in which completion of homework is reinforced will result in the best outcomes. The mechanisms by which the interventions result in behavior change will be the specific focus of attention in this study.